JP7417515B2 - 活動性好酸球性食道炎を治療する方法 - Google Patents

活動性好酸球性食道炎を治療する方法 Download PDF

Info

Publication number
JP7417515B2
JP7417515B2 JP2020505844A JP2020505844A JP7417515B2 JP 7417515 B2 JP7417515 B2 JP 7417515B2 JP 2020505844 A JP2020505844 A JP 2020505844A JP 2020505844 A JP2020505844 A JP 2020505844A JP 7417515 B2 JP7417515 B2 JP 7417515B2
Authority
JP
Japan
Prior art keywords
patient
dose
eoe
pathway inhibitor
esophageal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020505844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529434A5 (enExample
JP2020529434A (ja
Inventor
アレン・ラディン
ジェニファー・ディー・ハミルトン
レーダ・マンネン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of JP2020529434A publication Critical patent/JP2020529434A/ja
Publication of JP2020529434A5 publication Critical patent/JP2020529434A5/ja
Priority to JP2023192683A priority Critical patent/JP7811933B2/ja
Application granted granted Critical
Publication of JP7417515B2 publication Critical patent/JP7417515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020505844A 2017-08-04 2018-08-03 活動性好酸球性食道炎を治療する方法 Active JP7417515B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192683A JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US62/541,242 2017-08-04
US201762561593P 2017-09-21 2017-09-21
US62/561,593 2017-09-21
EP18305252.1 2018-03-08
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192683A Division JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Publications (3)

Publication Number Publication Date
JP2020529434A JP2020529434A (ja) 2020-10-08
JP2020529434A5 JP2020529434A5 (enExample) 2021-09-02
JP7417515B2 true JP7417515B2 (ja) 2024-01-18

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505844A Active JP7417515B2 (ja) 2017-08-04 2018-08-03 活動性好酸球性食道炎を治療する方法
JP2023192683A Active JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192683A Active JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Country Status (9)

Country Link
EP (1) EP3661551A1 (enExample)
JP (2) JP7417515B2 (enExample)
KR (2) KR102719720B1 (enExample)
CN (1) CN111032084A (enExample)
AU (2) AU2018311981B2 (enExample)
CA (1) CA3071528A1 (enExample)
IL (2) IL315556A (enExample)
MA (1) MA49744A (enExample)
MX (2) MX2020001305A (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7862322B2 (ja) * 2020-05-22 2026-05-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
GB202102277D0 (en) * 2021-02-18 2021-04-07 Nordic Bioscience As Immunoassay for detecting Eosinophilic Esophagitis
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
CN117085122A (zh) * 2022-04-29 2023-11-21 中山康方生物医药有限公司 抗人il-4ra的抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528207A (ja) 2013-07-11 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528207A (ja) 2013-07-11 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kwiatek, M. A. et al.，Mechanical properties of the esophagus in eosinophilic esophagitis，Gastroenterology，2011年，Vol.140, No.1，p.82-90，doi:10.1053/j.gastro.2010.09.037
藤原 靖弘 ほか，好酸球性食道炎の分子機構にもとづく治療戦略，G.I.Research，2016年，第24巻, 第3号，p.181-186
阿部 靖彦 ほか，好酸球性食道炎の診断，Gastroenterological Endoscopy，2014年，第56巻，第9号，p.3378-3393

Also Published As

Publication number Publication date
RU2020109331A (ru) 2021-09-06
IL315556A (en) 2024-11-01
JP2024016237A (ja) 2024-02-06
AU2025200955A1 (en) 2025-03-06
EP3661551A1 (en) 2020-06-10
IL272245A (en) 2020-03-31
AU2018311981B2 (en) 2024-11-14
AU2018311981A1 (en) 2020-02-20
MX2024012777A (es) 2024-11-08
KR102719720B1 (ko) 2024-10-22
CA3071528A1 (en) 2019-02-07
JP2020529434A (ja) 2020-10-08
IL272245B2 (en) 2025-02-01
IL272245B1 (en) 2024-10-01
KR20240152980A (ko) 2024-10-22
KR20200035442A (ko) 2020-04-03
JP7811933B2 (ja) 2026-02-06
CN111032084A (zh) 2020-04-17
MX2020001305A (es) 2020-03-09
MA49744A (fr) 2020-06-10
RU2020109331A3 (enExample) 2021-12-28

Similar Documents

Publication Publication Date Title
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
US12291571B2 (en) Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
HK40029391A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240105

R150 Certificate of patent or registration of utility model

Ref document number: 7417515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150